OncoSil Medical Statistics

Total Valuation

OncoSil Medical has a market cap or net worth of AUD 18.43 million. The enterprise value is 10.03 million.

Market Cap	18.43M
Enterprise Value	10.03M

Important Dates

The next estimated earnings date is Friday, May 30, 2025.

Earnings Date	May 30, 2025
Ex-Dividend Date	n/a

Share Statistics

OncoSil Medical has 4.61 billion shares outstanding. The number of shares has increased by 98.54% in one year.

Current Share Class	n/a
Shares Outstanding	4.61B
Shares Change (YoY)	+98.54%
Shares Change (QoQ)	+61.39%
Owned by Insiders (%)	11.20%
Owned by Institutions (%)	11.68%
Float	3.80B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.75
PB Ratio	2.15
P/TBV Ratio	2.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.80
EV / Sales	5.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.78

Financial Position

The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.01.

Current Ratio	3.81
Quick Ratio	3.61
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -199.38% and return on invested capital (ROIC) is -122.79%.

Return on Equity (ROE)	-199.38%
Return on Assets (ROA)	-87.77%
Return on Invested Capital (ROIC)	-122.79%
Return on Capital Employed (ROCE)	-146.49%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.21
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.00% in the last 52 weeks. The beta is 1.09, so OncoSil Medical's price volatility has been similar to the market average.

Beta (5Y)	1.09
52-Week Price Change	-20.00%
50-Day Moving Average	0.01
200-Day Moving Average	0.01
Relative Strength Index (RSI)	42.68
Average Volume (20 Days)	2,546,625

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OncoSil Medical had revenue of AUD 1.91 million and -12.60 million in losses. Loss per share was -0.00.

Revenue	1.91M
Gross Profit	256,555
Operating Income	-12.59M
Pretax Income	-12.60M
Net Income	-12.60M
EBITDA	-12.59M
EBIT	-12.59M
Loss Per Share	-0.00

Full Income Statement

Balance Sheet

The company has 8.47 million in cash and 70,843 in debt, giving a net cash position of 8.40 million or 0.00 per share.

Cash & Cash Equivalents	8.47M
Total Debt	70,843
Net Cash	8.40M
Net Cash Per Share	0.00
Equity (Book Value)	8.56M
Book Value Per Share	0.00
Working Capital	8.17M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.63 million and capital expenditures -208,405, giving a free cash flow of -12.84 million.

Operating Cash Flow	-12.63M
Capital Expenditures	-208,405
Free Cash Flow	-12.84M
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross Margin	13.43%
Operating Margin	-659.37%
Pretax Margin	-659.86%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OncoSil Medical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-98.54%
Shareholder Yield	-98.54%
Earnings Yield	-68.40%
FCF Yield	-69.69%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

OncoSil Medical has an Altman Z-Score of -9.13. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-9.13
Piotroski F-Score	n/a